Establishment and Evaluation to the Effects of a Clinical Pathway for Acute Ischemic Stroke

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

314 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-05-31

Study Completion Date

2011-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether the clinical pathway for acute ischemic stroke(with combination of traditional Chinese medicine and western medicine) is able to improve the outcome of acute ischemic stroke and evaluate its effect on hospital day and cost, etc. Meanwhile, the study will discuss the safety and efficiency of this kind of Clinical Pathway

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

AISTCM-Outcome Measurement of Acute Ischemic Stroke With Traditional Chinese Medicine

NCT00351806

Cerebral Infarction

COMPLETED PHASE4

Evidence-based Evaluation of TCM Key Syndrome Differentiation and Treatment for Acute Ischemic Stroke

NCT04199455

Ischemic Stroke

UNKNOWN PHASE4

Traditional Chinese Medicine Intervention for Ischemic Cerebrovascular Disease and Diabetes Mellitus: An Efficacy Comparative Study

NCT07121088

Ischemic Cerebral Infarction Diabetes Mellitus

NOT_YET_RECRUITING PHASE4

Efficacy and Safety of Reperfusion Therapy for Minor Ischemic Stroke in China

NCT07322835

Minor Ischemic Stroke

NOT_YET_RECRUITING

SouthErn China REgisTry for Stroke on Traditional Chinese Medicine

NCT03380481

Stroke Cerebral Infarction Transient Ischemic Attack +2 more

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Eligibility Ages Eligible for Study: 18 Years to 85 Years Genders Eligible for Study: Both Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

Those clinically diagnosed with acute ischemic stroke ； 18-85 years old； Over 6 hours and within 14 days from onset 4\<=NIHSS \<=22; Informed consent signed by patient or his/her family ；

Exclusion Criteria:

Hemorrhagic stroke; Cerebral hernia; Serious heart, liver, lung, kidney functional failure，malignancy; Not cooperative with physician; Psychological disorder; Already taken part in other clinical drug trial within the past 3 months

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Ischemic Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

pathway

aspirin，Chinese herbs；acupuncture；rehabilitation；health education；

Group Type EXPERIMENTAL

aspirin，chinese herbs；

Intervention Type DRUG

aspirin 300mg/100mg,qd,chinese herbs, one dose ，qd

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

aspirin，chinese herbs；

aspirin 300mg/100mg,qd,chinese herbs, one dose ，qd

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Bayer

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ischemic stroke diagnosed with both criteria of traditional Chinese medicine and western medicine；
* 18-85 years old；
* Over 6 hours and within 14 days from onset
* 4\<=NIHSS \<=22;
* Informed consent signed by patient or his/her family ；

Exclusion Criteria

* Hemorrhagic stroke;
* Cerebral hernia;
* Serious heart, liver, lung, kidney functional failure,malignancy;
* Not cooperative with physician;
* Psychological disorder;
* Already taken part in other clinical drug trial within the past 3 months

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No